NextGen Pulmocore 12 gene panel (SP263)
NextGen Pulmocore 12 gene panel (SP263)** Price
Brief Details
What is a NextGen Pulmocore 12 Gene Panel (SP263)?
The NextGen Pulmocore 12 Gene Panel (SP263) is an advanced diagnostic test that uses Next-Generation Sequencing (NGS) technology to analyse the genetic makeup of lung cancer cells. This comprehensive test examines tissue samples from lung tumours to identify specific genetic changes that can guide personalised treatment decisions for patients with lung cancer, particularly non-small cell lung cancer (NSCLC).
The test helps doctors determine the most effective targeted therapies and immunotherapy options for each patient's unique cancer profile.
What does the NextGen Pulmocore 12 Gene Panel (SP263) measure?
This advanced genetic test measures several important biomarkers that guide lung cancer treatment:
- Genetic mutations in 12 key genes - Identifies specific changes in genes like EGFR, ALK, ROS1, BRAF, and KRAS that drive cancer growth.
- Gene fusions - Detects abnormal gene combinations that can make cancers respond to targeted drugs.
- Copy number variations - Measures gene amplifications, particularly MET amplification.
- PD-L1 protein expression - Uses the SP263 assay to measure levels of this protein that affects immune system response.
- Short genetic changes - Identifies small insertions and deletions in cancer-related genes.
- Treatment-relevant mutations - Focuses on genetic changes that have approved targeted therapy options.
NextGen Pulmocore 12 Gene Panel (SP263): Who Needs It and Why It's Done
What Symptoms May Call for a NextGen Pulmocore 12 Gene Panel (SP263)?
This test is ordered after lung cancer diagnosis, not based on initial symptoms. However, the symptoms that typically lead to lung cancer diagnosis include:
- Persistent cough that doesn't improve with treatment
- Coughing up blood or rust-coloured sputum
- Chest pain that worsens with breathing or coughing
- Unexplained weight loss and reduced appetite
- Shortness of breath or wheezing sounds
- Hoarseness that persists for weeks
- Feeling unusually tired or weak
- Recurring respiratory infections like pneumonia
Who should get a NextGen Pulmocore 12 Gene Panel (SP263)?
This specialised test is recommended for specific patient groups:
- Patients diagnosed with Non-Small Cell Lung Cancer - Especially those with advanced or metastatic disease.
- Individuals being considered for targeted therapy - To identify specific genetic mutations that respond to precision medicines.
- Patients eligible for immunotherapy - To measure PD-L1 levels that predict treatment response.
- Those with adenocarcinoma subtype - A common form of NSCLC that often has targetable mutations.
- Patients seeking personalised treatment options - To move beyond standard chemotherapy approaches.
Why is a NextGen Pulmocore 12 Gene Panel (SP263) done?
This test creates a detailed molecular profile of your lung tumour, enabling your oncologist to select the most precise and effective treatment based on your cancer's unique genetic characteristics rather than using a one-size-fits-all approach.
Importance of a NextGen Pulmocore 12 Gene Panel (SP263)
This genetic test represents a breakthrough in personalised lung cancer care. It transforms treatment from guesswork to precision medicine by identifying specific molecular targets within your tumour. The test results directly determine whether you're eligible for targeted therapies that can be significantly more effective than traditional chemotherapy, often with fewer side effects.
By matching patients to the right treatment from the start, this panel improves outcomes, reduces unnecessary treatments, and helps avoid therapies that won't work for your specific cancer type. The PD-L1 component also identifies patients who may benefit from immunotherapy, which has revolutionised cancer treatment by harnessing your body's own immune system to fight cancer cells.
NextGen Pulmocore 12 Gene Panel (SP263) Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Pulmocore 12 Gene Panel (SP263)?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select NextGen Pulmocore 12 Gene Panel (SP263), choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is home sample collection for NextGen Pulmocore 12 Gene Panel (SP263) available near you?
No, Metropolis Healthcare does not provide home sample collection for the NextGen Pulmocore 12 Gene Panel (SP263). This test requires a tissue sample from your lung tumour, which must be collected through a biopsy procedure at a medical facility. However, once your tissue sample is available, our NABL and CAP accredited laboratories ensure accurate genetic analysis with reliable results.
How Long Does It Take to Get a NextGen Pulmocore 12 Gene Panel (SP263) Report?
Reports are usually available after 12 days once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where can I see or get NextGen Pulmocore 12 Gene Panel (SP263) results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Pulmocore 12 Gene Panel (SP263) Results
What Your NextGen Pulmocore 12 Gene Panel (SP263) Results May Indicate
Your genetic test results provide crucial information about your cancer's molecular characteristics. Here's what the different findings mean:
|
Parameters |
Result Type |
Positive/Detected |
Negative/Not Detected |
|
Gene Mutations (EGFR, ALK, ROS1, etc.) |
Detected/Not Detected |
Specific targeted therapy may be available |
Standard treatment options may be considered |
|
Gene Fusions |
Present/Absent |
May respond to fusion-specific targeted drugs |
Fusion-targeted therapy not indicated |
|
PD-L1 Expression (SP263) |
Percentage Score |
Higher scores suggest immunotherapy benefit |
Lower scores may indicate limited immunotherapy response |
|
MET Amplification |
Amplified/Not Amplified |
MET inhibitor therapy may be beneficial |
MET-targeted treatment not recommended |
Conditions that May Affect NextGen Pulmocore 12 Gene Panel (SP263) Accuracy
Several factors can influence the accuracy of your genetic test results and should be discussed with your healthcare team:
- Tissue sample quality - Poor preservation or insufficient tumour content can affect results.
- Previous cancer treatments - Prior chemotherapy or radiation may alter genetic patterns.
- Tumour heterogeneity - Different areas of the same tumour may have varying genetic profiles.
- Sample age - Very old tissue blocks may have degraded genetic material.
- Contamination with normal cells - High levels of non-cancerous tissue can dilute results.
- Technical factors - Laboratory processing conditions and equipment calibration.
- Biopsy location - Samples from different tumour sites may show genetic variations.
How is a NextGen Pulmocore 12 Gene Panel (SP263) Done?
This advanced genetic test involves several carefully coordinated steps to ensure accurate results:
- Tissue collection - A lung biopsy is performed to obtain tumour tissue, usually during a bronchoscopy or CT-guided needle biopsy.
- Sample preparation - The tissue is processed and embedded in paraffin wax to preserve the genetic material.
- Quality assessment - Laboratory experts evaluate the tissue to ensure adequate tumour content for testing.
- DNA/RNA extraction - Genetic material is carefully extracted from the cancer cells.
- Library preparation - The genetic material is prepared for sequencing using specialised techniques.
- Next-generation sequencing - Advanced machines read the genetic code of your tumour.
- Data analysis - Sophisticated software identifies mutations and genetic changes.
- Expert review - Qualified pathologists interpret the results and prepare your report.
How Should You Prepare for a NextGen Pulmocore 12 Gene Panel (SP263)?
Preparing for this genetic test involves coordination with your healthcare team:
- No fasting required - You can eat and drink normally as this test uses tissue samples, not blood.
- Provide complete medical history - Share all previous cancer treatments and medications with your doctor.
- Bring histopathology reports - Your doctor will need previous biopsy results and pathology findings.
- Discuss current medications - Some drugs may need to be reviewed before the biopsy procedure.
- Follow biopsy preparation instructions - Your doctor will provide specific guidelines for the tissue collection procedure.
- Arrange transportation - You may need someone to drive you home after the biopsy.
Diseases that a NextGen Pulmocore 12 Gene Panel (SP263) Can Help Detect
This comprehensive genetic panel helps identify and characterise various lung cancer conditions:
- Non-Small Cell Lung Cancer (NSCLC) - The most common type of lung cancer with multiple genetic subtypes.
- Adenocarcinoma - A specific form of NSCLC that often carries targetable mutations.
- Squamous cell carcinoma - Another NSCLC subtype that may have specific genetic characteristics.
- Large cell carcinoma - A less common but aggressive form of NSCLC.
- EGFR-mutated lung cancer - Cancers with specific mutations that respond to targeted drugs.
- ALK-positive lung cancer - Tumours with ALK gene rearrangements that have targeted treatment options.
- ROS1-positive lung cancer - Rare cancers with ROS1 fusions that respond to specific inhibitors.
NextGen Pulmocore 12 Gene Panel (SP263)/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive lung cancer testing options to support your diagnosis and treatment planning:
|
Test/Package Name |
Purpose/Highlights |
|
Focuses on the three most common targetable mutations in lung cancer |
|
|
Comprehensive profile for Non-Small Cell Lung Cancer diagnosis and staging |
|
|
Next-generation sequencing panel for broader genetic analysis of lung cancers |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.